Mike Dybbs

Mike Dybbs is a Partner at Samsara BioCapital, a leading venture capital firm based in Palo Alto, California, specializing in life sciences, oncology, and digital healthcare investments. In his role, he oversees a diverse portfolio of private and public companies, actively guiding strategy and governance as a board member for several prominent biotech firms. Dybbs is responsible for sourcing, evaluating, and managing investments across the full risk cycle, from seed-stage startups to publicly traded equities.

Dybbs focuses primarily on the life sciences sector, with deep expertise in oncology, immunology, and digital health. He has played a pivotal role in supporting innovative companies such as Delfi Diagnostics, Enara Bio, Fluent, Ionpath, Nkarta Therapeutics, and Sutro Biopharma. His investment approach emphasizes scientific innovation and scalable business models, contributing to the advancement of novel therapies and technologies in the healthcare industry.

Prior to joining Samsara BioCapital in 2017, Dybbs was a Partner at New Leaf Venture Partners, where he served on the boards of Dimension Therapeutics and Principia Biopharma. He previously held leadership roles at the Boston Consulting Group, advising biotech and pharmaceutical clients on strategic initiatives. Dybbs holds an A.B. in Biochemical Sciences from Harvard University and a Ph.D. in Molecular Biology from the University of California, Berkeley, where he was awarded a Howard Hughes Medical Institute fellowship. His scientific background and extensive industry experience have made him a respected figure in the life sciences investment community.